Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why

Loading... Patients have responded positively to HyBryte therapy. Three of the four subjects who have completed at least 12 weeks of therapy already achieved "Treatment Success." "In the Phase 3 FLASH study, HyBryte was shown to be efficacious with a promising safety profile. With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments. The open-label study (protocol HPN-CTCL-04) enrolled ten patients. The Princeton, New Jersey ...